CDXS - Codexis Inc Stock Price, Fair Value and News

3.47USD-0.06 (-1.70%)Delayed as of 08 May 2024, 12:49 pm ET

Market Summary

USD3.47-0.06

Delayedas of 08 May 2024, 12:49 pm

-1.70%

CDXS Stock Price

View Fullscreen

CDXS RSI Chart

CDXS Valuation

Market Cap

249.1M

Price/Earnings (Trailing)

-3.82

Price/Sales (Trailing)

3.36

EV/EBITDA

-3.66

Price/Free Cashflow

-4.59

CDXS Price/Sales (Trailing)

CDXS Profitability

EBT Margin

-87.65%

Return on Equity

-82.16%

Return on Assets

-43.55%

Free Cashflow Yield

-21.77%

CDXS Fundamentals

CDXS Revenue

Revenue (TTM)

74.2M

Rev. Growth (Yr)

31.51%

Rev. Growth (Qtr)

-35.72%

CDXS Earnings

Earnings (TTM)

-65.1M

Earnings Growth (Yr)

49.13%

Earnings Growth (Qtr)

-59.97%

Breaking Down CDXS Revenue

52 Week Range

1.453.84

(Low)(High)

Last 7 days

21.7%

Last 30 days

11.0%

Last 90 days

27.3%

Trailing 12 Months

3.8%

How does CDXS drawdown profile look like?

CDXS Financial Health

Current Ratio

3.71

Debt/Equity

0.35

Debt/Cashflow

-1.82

CDXS Investor Care

Shares Dilution (1Y)

5.68%

Diluted EPS (TTM)

-0.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	74.2M	0	0	0
2023	116.2M	99.1M	74.0M	70.1M
2022	122.1M	135.0M	132.7M	138.6M
2021	72.4M	82.9M	101.3M	104.8M
2020	67.5M	70.2M	66.7M	69.1M
2019	62.1M	60.9M	65.9M	68.5M
2018	56.1M	59.3M	66.2M	60.6M
2017	48.8M	43.2M	38.3M	50.0M
2016	43.0M	53.0M	50.5M	48.8M
2015	35.0M	34.5M	44.4M	41.8M
2014	27.5M	27.1M	30.6M	35.3M
2013	68.6M	52.7M	30.3M	31.9M
2012	124.0M	120.8M	113.9M	88.3M
2011	112.4M	114.0M	120.2M	123.9M
2010	0	91.0M	99.0M	107.1M
2009	0	0	0	82.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Codexis Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 01, 2024	ryali sriram	acquired	-	-	52,350	chief financial officer
Jan 01, 2024	dilly stephen george	acquired	-	-	143,425	see remarks
Jan 01, 2024	fitzgerald margaret nell	acquired	-	-	52,350	see remarks
Jan 01, 2024	norrett kevin	acquired	-	-	52,350	chief operating officer
Nov 15, 2023	dorgan byron l	sold	-42,168	2.1084	-20,000	-
Sep 11, 2023	norrett kevin	bought	15,479	1.7199	9,000	chief operating officer
Sep 08, 2023	ryali sriram	bought	19,856	1.7044	11,650	chief financial officer
Sep 08, 2023	dilly stephen george	bought	100,952	1.7263	58,479	see remarks
Sep 08, 2023	fitzgerald margaret nell	bought	20,064	1.6955	11,834	see remarks
Jun 13, 2023	smith david v	acquired	-	-	34,602	-

Which funds bought or sold CDXS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	SG Americas Securities, LLC	reduced	-32.41	-22,000	74,000	-%
May 06, 2024	Quantbot Technologies LP	added	53.19	8,202	19,097	-%
May 06, 2024	Parallel Advisors, LLC	new	-	698	698	-%
May 03, 2024	HUNTINGTON NATIONAL BANK	unchanged	-	1.00	7.00	-%
May 03, 2024	GSA CAPITAL PARTNERS LLP	reduced	-94.07	-2,380,000	173,000	0.01%
May 03, 2024	VALLEY WEALTH MANAGERS, INC.	unchanged	-	22.00	175	-%
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	added	1.22	592	4,328	-%
May 02, 2024	Salomon & Ludwin, LLC	unchanged	-	2,400	5,235	-%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	new	-	96,665	96,665	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%

Are Funds Buying or Selling CDXS?

Are funds buying CDXS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CDXS

No. of Funds

Unveiling Codexis Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	6.6%	4,592,903	SC 13G/A
Feb 13, 2024	vanguard group inc	5.91%	4,128,428	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Jan 24, 2024	blackrock inc.	10.3%	7,196,414	SC 13G/A
Jan 08, 2024	baillie gifford & co	4.90%	3,419,093	SC 13G/A
Aug 08, 2023	blackrock inc.	10.4%	6,932,344	SC 13G/A
Feb 14, 2023	nantahala capital management, llc	6.8%	4,487,782	SC 13G/A
Feb 14, 2023	casdin capital, llc	0%	0	SC 13G/A
Feb 10, 2023	ark investment management llc	6.00%	3,941,985	SC 13G/A
Feb 09, 2023	vanguard group inc	5.54%	3,642,208	SC 13G/A

Recent SEC filings of Codexis Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	S-3	S-3
May 02, 2024	8-K	Current Report
May 02, 2024	10-Q	Quarterly Report
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Mar 06, 2024	8-K	Current Report
Feb 28, 2024	8-K	Current Report
Feb 28, 2024	10-K	Annual Report
Feb 16, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Codexis Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Codexis Inc News

Latest updates

Codexis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-35.7%	17,073,000	26,561,000	9,277,000	21,323,000	12,982,000	30,374,500	34,470,000	38,406,000	35,340,000	24,500,500	36,769,000	25,453,000	18,032,000	21,033,500	18,385,000	14,967,000	14,670,000	18,650,000	21,906,000	12,319,000	15,583,000
Costs and Expenses	10.2%	28,961,000	26,279,500	41,337,000	33,949,000	36,647,000	43,624,500	45,106,000	41,015,000	43,726,000	34,886,000	35,439,000	29,939,000	27,187,000	24,956,500	24,449,000	21,074,000	22,497,000	19,596,500	21,647,000	18,942,000	20,822,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,647,000	18,942,000	20,822,000
S&GA Expenses	5.5%	12,860,000	12,184,000	12,302,000	13,365,000	15,399,000	12,312,500	13,499,000	10,656,000	15,705,000	11,723,000	13,407,000	12,795,000	11,398,000	8,741,500	8,797,000	8,522,000	8,989,000	7,322,000	7,869,000	7,896,000	8,415,000
R&D Expenses	0.1%	11,246,000	11,234,000	13,662,000	17,334,000	16,655,000	19,689,000	21,821,000	19,089,000	19,500,000	16,357,000	15,165,000	12,826,000	11,571,000	10,355,000	12,010,000	10,853,000	10,967,000	8,872,500	8,711,000	8,274,000	8,016,000
EBITDA Margin	20.6%	-0.80	-1.01	-1.02	-0.51	-0.36	-0.20	-0.20	-0.11	-0.14	-0.17	-0.12	-0.25	-	-	-	-	-	-	-	-	-
Interest Expenses	818.8%	147,000	16,000	18,000	3,000	7,000	12,000	10,000	7,000	5,000	8,000	3,000	-	3,000	37,000	11,000	-	4,000	33,000	7,000	-13,000	22,000
Income Taxes	-71.4%	10,000	35,000	9,000	9,000	16,000	151,000	8,000	108,000	9,000	68,500	110,000	8,000	2,000	8,000	19,000	307,000	5,000	5,000	-7,000	16,000	3,000
Earnings Before Taxes	-60.6%	-11,495,000	-7,157,000	-34,899,000	-11,514,000	-22,601,000	-12,453,000	-9,984,000	-2,532,000	-8,347,000	-10,121,500	2,354,000	-4,257,000	-9,066,000	-3,912,000	-6,075,000	-6,037,000	-7,647,000	-630,000	336,000	-6,491,000	-5,133,000
EBT Margin	19.3%	-0.88	-1.09	-1.10	-0.57	-0.41	-0.24	-0.23	-0.14	-0.17	-0.20	-0.15	-0.28	-	-	-	-	-	-	-	-	-
Net Income	-60.0%	-11,505,000	-7,192,000	-34,908,000	-11,523,000	-22,617,000	-12,604,000	-9,992,000	-2,640,000	-8,356,000	-10,190,000	2,244,000	-4,265,000	-9,068,000	-3,920,000	-6,094,000	-6,344,000	-7,652,000	-635,000	343,000	-6,507,000	-5,136,000
Net Income Margin	19.3%	-0.88	-1.09	-1.10	-0.57	-0.41	-0.24	-0.23	-0.14	-0.17	-0.20	-0.15	-0.28	-	-	-	-	-	-	-	-	-
Free Cashflow	16.3%	-8,919,000	-10,657,000	-16,980,000	-17,668,000	-11,751,000	4,950,000	18,424,000	-4,122,000	-16,275,000	-4,820,000	-4,196,000	-10,089,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	9.5%	150	137	154	207	218	250	235	235	235	246	228	212	212	222	138	142	149	149	146	147	101
Current Assets	15.5%	108	93.00	103	120	130	163	146	145	145	162	174	172	174	184	103	106	115	114	110	110	64.00
Cash Equivalents	-8.4%	60.00	65.00	75.00	92.00	103	114	109	90.00	94.00	117	119	130	140	151	72.00	76.00	87.00	92.00	92.00	93.00	47.00
Inventory	-9.1%	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	1.00	1.00
Net PPE	-5.3%	15.00	15.00	15.00	23.00	24.00	23.00	23.00	24.00	23.00	21.00	16.00	11.00	10.00	10.00	7.00	7.00	7.00	6.00	6.00	5.00	5.00
Goodwill	0%	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	40.7%	70.00	50.00	63.00	83.00	92.00	106	81.00	76.00	77.00	82.00	58.00	50.00	48.00	52.00	47.00	47.00	50.00	44.00	44.00	48.00	50.00
Current Liabilities	-18.8%	29.00	36.00	38.00	36.00	38.00	49.00	32.00	30.00	29.00	33.00	33.00	24.00	23.00	25.00	20.00	19.00	22.00	15.00	15.00	17.00	19.00
Long Term Debt	-	28.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-8.5%	79.00	87.00	92.00	124	126	145	154	159	159	164	169	163	164	170	91.00	95.00	99.00	106	103	99.00	51.00
Retained Earnings	-2.3%	-509	-497	-490	-455	-443	-421	-408	-398	-396	-387	-377	-379	-375	-366	-362	-356	-350	-342	-341	-342	-335
Additional Paid-In Capital	0.7%	588	584	582	580	570	566	563	558	555	552	547	543	539	537	453	451	449	448	444	441	387
Accumulated Depreciation	1.5%	40.00	39.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.9%	71.00	70.00	70.00	70.00	67.00	66.00	65.00	65.00	65.00	65.00	65.00	64.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	122	-	-	-	384	-	-	-	738	-	-	-	656	-	-	-	1,070	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	29.4%	-7,789	-11,037	-16,302	-16,087	-9,212	4,917	19,734	-2,181	-11,186	660	-192	-8,295	-6,440	-1,492	-3,474	-10,073	-1,425	-3,661	-990	-5,058	-2,851
Share Based Compensation	46.6%	3,171	2,163	2,283	2,716	2,809	2,931	4,531	3,231	3,838	3,046	3,016	2,844	2,687	1,636	1,984	1,939	2,169	1,160	1,732	1,988	2,063
Cashflow From Investing	-2687.2%	-28,563	1,104	-1,107	-1,571	-3,284	33.00	-1,309	-2,220	-10,082	-5,480	-10,997	-2,412	-2,533	-2,488	-770	-1,729	-761	-414	-1,994	-812	-445
Cashflow From Financing	-	29,281	-	-108	6,923	1,352	339	133	233	-1,280	2,426	868	456	17.00	81,586	125	116	-1,019	2,422	1,688	51,933	-2,082

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CDXS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 17,073	$ 12,982
Costs and operating expenses:
Cost of product revenue	4,855	4,521
Research and development	11,246	16,655
Selling, general and administrative	12,860	15,399
Restructuring charges	0	72
Total costs and operating expenses	28,961	36,647
Loss from operations	(11,888)	(23,665)
Interest income	909	1,089
Other expense, net	(516)	(25)
Loss before income taxes	(11,495)	(22,601)
Provision for income taxes	10	16
Net loss	$ (11,505)	$ (22,617)
Net loss per share, basic (in dollars per share)	$ (0.16)	$ (0.34)
Net loss per share, diluted (in dollars per share)	$ (0.16)	$ (0.34)
Weighted average common stock shares used in computing net loss per share, basic (in shares)	69,854	65,931
Weighted average common stock shares used in computing net loss per share, diluted (in shares)	69,854	65,931
Product revenue
Revenues:
Total revenues	$ 9,551	$ 8,364
Research and development revenue
Revenues:
Total revenues	$ 7,522	$ 4,618

CDXS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 58,046	$ 65,116
Restricted cash, current	518	519
Short-term investments	27,469	0
Financial assets:
Accounts receivable	6,240	10,036
Contract assets	2,571	815
Unbilled receivables	5,459	9,142
Total financial assets	14,270	19,993
Less: allowances	(65)	(65)
Total financial assets, net	14,205	19,928
Inventories	2,441	2,685
Prepaid expenses and other current assets	5,269	5,218
Total current assets	107,948	93,466
Restricted cash	1,062	1,062
Investment in non-marketable equity securities	9,700	9,700
Right-of-use assets - Operating leases, net	12,364	13,137
Property and equipment, net	14,668	15,487
Goodwill	2,463	2,463
Other non-current assets	1,354	1,246
Total assets	149,559	136,561
Current liabilities:
Accounts payable	3,465	5,947
Accrued compensation	6,502	11,246
Other accrued liabilities	5,374	4,735
Current portion of lease obligations - Operating leases	3,879	3,781
Deferred revenue	9,860	10,121
Total current liabilities	29,080	35,830
Deferred revenue, net of current portion	630	640
Long-term lease obligations - Operating leases	11,232	12,243
Long-term debt	28,102	0
Other long-term liabilities	1,248	1,233
Total liabilities	70,292	49,946
Commitments and Contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.0001 par value per share; 200,000 shares authorized; 70,554 shares and 69,905 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	7	7
Additional paid-in capital	588,311	584,138
Accumulated other comprehensive loss	(16)	0
Accumulated deficit	(509,035)	(497,530)
Total stockholders' equity	79,267	86,615
Total liabilities and stockholders' equity	$ 149,559	$ 136,561

About Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with NestlÃƒÂ© Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CEO	Dr. Stephen George Dilly MBBS, Ph.D.
WEBSITE	codexis.com
INDUSTRY	Biotechnology
EMPLOYEES	248

Codexis Inc Frequently Asked Questions

What is the ticker symbol for Codexis Inc? What does CDXS stand for in stocks?

CDXS is the stock ticker symbol of Codexis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Codexis Inc (CDXS)?

As of Tue May 07 2024, market cap of Codexis Inc is 249.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDXS stock?

You can check CDXS's fair value in chart for subscribers.

What is the fair value of CDXS stock?

You can check CDXS's fair value in chart for subscribers. The fair value of Codexis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Codexis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Codexis Inc a good stock to buy?

The fair value guage provides a quick view whether CDXS is over valued or under valued. Whether Codexis Inc is cheap or expensive depends on the assumptions which impact Codexis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDXS.

What is Codexis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, CDXS's PE ratio (Price to Earnings) is -3.82 and Price to Sales (PS) ratio is 3.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDXS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Codexis Inc's stock?

In the past 10 years, Codexis Inc has provided 0.086 (multiply by 100 for percentage) rate of return.